Sumitomo Dainippon Pharma Stock Cash Flow From Operations
| DNPUFDelisted Stock | USD 4.37 0.00 0.00% |
Sumitomo Dainippon Pharma fundamentals help investors to digest information that contributes to Sumitomo Dainippon's financial success or failures. It also enables traders to predict the movement of Sumitomo Pink Sheet. The fundamental analysis module provides a way to measure Sumitomo Dainippon's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sumitomo Dainippon pink sheet.
Sumitomo |
Sumitomo Dainippon Pharma Company Cash Flow From Operations Analysis
Sumitomo Dainippon's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Sumitomo Dainippon Cash Flow From Operations | 31.24 B |
Most of Sumitomo Dainippon's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sumitomo Dainippon Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Sumitomo Dainippon Pharma has 31.24 B in Cash Flow From Operations. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash flow from operations for all United States stocks is significantly lower than that of the firm.
Sumitomo Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Dainippon's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Dainippon could also be used in its relative valuation, which is a method of valuing Sumitomo Dainippon by comparing valuation metrics of similar companies.Sumitomo Dainippon is currently under evaluation in cash flow from operations category among its peers.
Sumitomo Fundamentals
| Return On Equity | -0.0399 | |||
| Return On Asset | -0.0075 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.03) % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Insiders | 58.59 % | |||
| Shares Owned By Institutions | 19.60 % | |||
| Price To Earning | 4.79 X | |||
| Price To Book | 0.64 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 560.03 B | |||
| Gross Profit | 402.91 B | |||
| EBITDA | 124.36 B | |||
| Net Income | 56.41 B | |||
| Cash And Equivalents | 265.59 B | |||
| Cash Per Share | 668.50 X | |||
| Total Debt | 243.96 B | |||
| Debt To Equity | 0.36 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1,599 X | |||
| Cash Flow From Operations | 31.24 B | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 6.99 K | |||
| Beta | 0.31 | |||
| Market Capitalization | 2.64 B | |||
| Total Asset | 1.31 T | |||
| Retained Earnings | 349.13 B | |||
| Working Capital | 224.66 B | |||
| Current Asset | 384.35 B | |||
| Current Liabilities | 159.68 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 1.31 T | |||
| Last Dividend Paid | 28.0 |
About Sumitomo Dainippon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Dainippon Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Dainippon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Dainippon Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C | |
| FMC | FMC Corporation | |
| XYF | X Financial Class |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Sumitomo Pink Sheet
If you are still planning to invest in Sumitomo Dainippon Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sumitomo Dainippon's history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |